Skip to content

Follistatin Levels in Metabolically Healthy and Unhealthy Obese Individuals

Can Follistatin Levels Help Distinguish Between Metabolically Healthy and Unhealthy Obese Individuals

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06229899
Enrollment
62
Registered
2024-01-29
Start date
2022-01-15
Completion date
2023-01-15
Last updated
2024-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Brief summary

There is no clear boundary on which obese individuals should be considered metabolically healthy and which should be considered metabolically unhealthy. It is also not very clear whether the individuals who are considered metabolically healthy will remain healthy in the future. The objective of this study was to assess potential disparities in serum follistatin levels between these two distinct groups. Furthermore, the study sought to investigate whether this disparity could serve as a reliable indicator for distinguishing between metabolically healthy and unhealthy obese individuals.

Detailed description

Individuals with similar body mass indexes may have different metabolic health and cardiovascular risks. Research shows that some individuals with comparable body mass index (BMI) are metabolically healthy and have a lower risk of cardiovascular issues, while others are metabolically unhealthy and have a higher risk. Studies indicate that the lifestyles of metabolically healthy and unhealthy obese individuals, such as diet, physical activity, and sleep patterns, do not differ significantly, even though the individuals have similar levels of total or subcutaneous adiposity. However, it has been shown that metabolically healthy obese individuals tend to have lower levels of visceral adiposity compared to unhealthy ones. Patients with BMI≥30, who applied to the internal medicine clinic, were included in the study. Among these patients, those without criteria of metabolic syndrome other than an increase in waist circumference (blood pressure ≥130/85 mmHg, fasting blood sugar ≥100 mg/dl, triglycerides ≥150 mg/dl, HDL-cholesterol \<40 mg/dl in men and \<50 mg/dl in women) and without prediabetes were defined as metabolically healthy obese individuals. Those with at least 1 metabolic syndrome criterion other than an increase in waist circumference were classified as metabolically unhealthy obese individuals. The participants' fasting blood sugar levels, HbA1c levels, insulin levels, lipid panel results, liver enzymes levels,urea levels, creatinine levels, whole blood count, and thyroid hormones were examined. Anthropometric measurements including height,weight and waist circumference were also taken for each individual. Participants were then invited back to repeat follistatin levels.

Interventions

DIAGNOSTIC_TESTSerum follistatin levels

blood samples are taken

Sponsors

Goztepe Prof Dr Suleyman Yalcın City Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Having given consent to the study * Being over 18 years of age * Being under 60 years of age * Body mass index \>=30 kg/m2

Exclusion criteria

* Antidiabetic medication usage * obesity surgery * Antihypertensive medication usage * Those receiving lipid-lowering therapy * Pregnant women * Those with hypo/hyperthyroidism * Steroid use * Benign/malignant tumors * Advanced liver disease * Secondary causes of obesity

Design outcomes

Primary

MeasureTime frameDescription
relation between follistatin and metabolically healthy and unhealthy obesitybaselineThis study aims to examine the correlation between follistatin levels and both metabolically healthy and unhealthy individuals with obesity
threshold for follistatin in metabolic evaluation of obesitybaselineThe establishment of a threshold value for follistatin levels in assessing metabolic health in obese individuals.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026